Analytical Data
-
基因名
PI15
- Application
-
别名
PI15；CRISP8；P25TI；Peptidase inhibitor 15
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O43692
-
表达区间
61-258aa
-
氨基酸序列
YISQNDMIAI LDYHNQVRGK VFPPAANMEY MVWDENLAKS AEAWAATCIW DHGPSYLLRF LGQNLSVRTG RYRSILQLVK PWYDEVKDYA FPYPQDCNPR CPMRCFGPMC THYTQMVWAT SNRIGCAIHT CQNMNVWGSV WRRAVYLVCN YAPKGNWIGE APYKVGVPCS SCPPSYGGSC TDNLCFPGVT SNYLYWFK
-
分子量
29 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PI15, or PAI-1 (Plasminogen Activator Inhibitor-1) protein, is an important regulatory component in the fibrinolytic pathway, which is responsible for the breakdown of blood clots. Elevated levels of PI15 have been linked to various pathological conditions, including cardiovascular diseases, obesity, and certain types of cancer, due to its role in inhibiting tissue plasminogen activator and urokinase plasminogen activator. Researchers have shown interest in PI15 for its potential as a biomarker for disease progression and as a therapeutic target. Studies have indicated that modulating PI15 levels could influence clotting dynamics and tissue remodeling processes, making it a candidate for drug development. Furthermore, understanding the mechanisms regulating PI15 expression may offer insights into the pathophysiology of thrombotic disorders. Advances in recombinant protein technology have facilitated the production of PI15 for in vitro and in vivo studies, allowing for a deeper exploration of its functions and interactions within the circulatory system. Ongoing research aims to clarify the molecular pathways involving PI15 and identify how it can be effectively targeted to improve clinical outcomes in conditions characterized by abnormal fibrinolytic activity.
